A multicenter open-label experience on the response on psoriasis to adalimumab and effect of dose escalation in non-responders

The aphrodite project

G. A. Vena, A. Galluccio, C. De Simone, V. Mastrandrea, R. Buquicchio, S. La Greca, S. Dattola, A. Puglisi Guerra, L. Donato, F. Cantoresi, O. De Pita, M. Pezza, M. D'Agostino, R. Vernaci, A. Miracapillo, G. Velenti, N. Cassano

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

There is much evidence to show the efficacy of adalimumab, a human monoclonal antibody targeting tumour necrosis factor-alpha, in the treatment of plaque psoriasis. In this open-label experience, 147 high-need patients suffering from plaque psoriasis, with a mean Psoriasis Area and Severity Index (PASI) of 18.8, and concomitant psoriatic arthritis (PsA) received subcutaneous injections of 40 mg of adalimumab every other week (EOW). This was actually the dosage regimen recommended for PsA, as the drug had not then been approved for psoriasis at the time of the patients' enrolment. At week 12, an improvement of at least 50% of the PASI (PASI-50) was observed in 111 (77%) patients. Continuation of treatment in responders with adalimumab 40 mg EOW led to a sustained response, with the PASI-50 achieved by 97% of patients in the as-treated analysis at week 24 (PASI-75 in 82% and PASI-90 in 45% out of 109 patients who received EOW injections up to week 24). Thirty subjects who failed to attain the PASI-50 response at week 12 were treated with adalimumab 40 mg every week for a further 12 weeks. At week 24, 80% of these patients obtained a PASI-50 response after dose escalation. Tolerability was good in the majority of patients. Only two patients discontinued treatment because of an adverse event (repeated flu-like episodes and a pleuropericarditis of unknown origin, respectively).

Original languageEnglish
Pages (from-to)227-233
Number of pages7
JournalInternational Journal of Immunopathology and Pharmacology
Volume22
Issue number1
Publication statusPublished - Jan 2009

Fingerprint

Psoriasis
Psoriatic Arthritis
Adalimumab
Pericarditis
Subcutaneous Injections
Therapeutics
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Injections

Keywords

  • Adalimumab
  • Dose escalation
  • Psoriasis
  • Response
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Cite this

A multicenter open-label experience on the response on psoriasis to adalimumab and effect of dose escalation in non-responders : The aphrodite project. / Vena, G. A.; Galluccio, A.; De Simone, C.; Mastrandrea, V.; Buquicchio, R.; La Greca, S.; Dattola, S.; Puglisi Guerra, A.; Donato, L.; Cantoresi, F.; De Pita, O.; Pezza, M.; D'Agostino, M.; Vernaci, R.; Miracapillo, A.; Velenti, G.; Cassano, N.

In: International Journal of Immunopathology and Pharmacology, Vol. 22, No. 1, 01.2009, p. 227-233.

Research output: Contribution to journalArticle

Vena, GA, Galluccio, A, De Simone, C, Mastrandrea, V, Buquicchio, R, La Greca, S, Dattola, S, Puglisi Guerra, A, Donato, L, Cantoresi, F, De Pita, O, Pezza, M, D'Agostino, M, Vernaci, R, Miracapillo, A, Velenti, G & Cassano, N 2009, 'A multicenter open-label experience on the response on psoriasis to adalimumab and effect of dose escalation in non-responders: The aphrodite project', International Journal of Immunopathology and Pharmacology, vol. 22, no. 1, pp. 227-233.
Vena, G. A. ; Galluccio, A. ; De Simone, C. ; Mastrandrea, V. ; Buquicchio, R. ; La Greca, S. ; Dattola, S. ; Puglisi Guerra, A. ; Donato, L. ; Cantoresi, F. ; De Pita, O. ; Pezza, M. ; D'Agostino, M. ; Vernaci, R. ; Miracapillo, A. ; Velenti, G. ; Cassano, N. / A multicenter open-label experience on the response on psoriasis to adalimumab and effect of dose escalation in non-responders : The aphrodite project. In: International Journal of Immunopathology and Pharmacology. 2009 ; Vol. 22, No. 1. pp. 227-233.
@article{5a0551ca5b25472795576abe2c0f25ba,
title = "A multicenter open-label experience on the response on psoriasis to adalimumab and effect of dose escalation in non-responders: The aphrodite project",
abstract = "There is much evidence to show the efficacy of adalimumab, a human monoclonal antibody targeting tumour necrosis factor-alpha, in the treatment of plaque psoriasis. In this open-label experience, 147 high-need patients suffering from plaque psoriasis, with a mean Psoriasis Area and Severity Index (PASI) of 18.8, and concomitant psoriatic arthritis (PsA) received subcutaneous injections of 40 mg of adalimumab every other week (EOW). This was actually the dosage regimen recommended for PsA, as the drug had not then been approved for psoriasis at the time of the patients' enrolment. At week 12, an improvement of at least 50{\%} of the PASI (PASI-50) was observed in 111 (77{\%}) patients. Continuation of treatment in responders with adalimumab 40 mg EOW led to a sustained response, with the PASI-50 achieved by 97{\%} of patients in the as-treated analysis at week 24 (PASI-75 in 82{\%} and PASI-90 in 45{\%} out of 109 patients who received EOW injections up to week 24). Thirty subjects who failed to attain the PASI-50 response at week 12 were treated with adalimumab 40 mg every week for a further 12 weeks. At week 24, 80{\%} of these patients obtained a PASI-50 response after dose escalation. Tolerability was good in the majority of patients. Only two patients discontinued treatment because of an adverse event (repeated flu-like episodes and a pleuropericarditis of unknown origin, respectively).",
keywords = "Adalimumab, Dose escalation, Psoriasis, Response, Treatment",
author = "Vena, {G. A.} and A. Galluccio and {De Simone}, C. and V. Mastrandrea and R. Buquicchio and {La Greca}, S. and S. Dattola and {Puglisi Guerra}, A. and L. Donato and F. Cantoresi and {De Pita}, O. and M. Pezza and M. D'Agostino and R. Vernaci and A. Miracapillo and G. Velenti and N. Cassano",
year = "2009",
month = "1",
language = "English",
volume = "22",
pages = "227--233",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",
number = "1",

}

TY - JOUR

T1 - A multicenter open-label experience on the response on psoriasis to adalimumab and effect of dose escalation in non-responders

T2 - The aphrodite project

AU - Vena, G. A.

AU - Galluccio, A.

AU - De Simone, C.

AU - Mastrandrea, V.

AU - Buquicchio, R.

AU - La Greca, S.

AU - Dattola, S.

AU - Puglisi Guerra, A.

AU - Donato, L.

AU - Cantoresi, F.

AU - De Pita, O.

AU - Pezza, M.

AU - D'Agostino, M.

AU - Vernaci, R.

AU - Miracapillo, A.

AU - Velenti, G.

AU - Cassano, N.

PY - 2009/1

Y1 - 2009/1

N2 - There is much evidence to show the efficacy of adalimumab, a human monoclonal antibody targeting tumour necrosis factor-alpha, in the treatment of plaque psoriasis. In this open-label experience, 147 high-need patients suffering from plaque psoriasis, with a mean Psoriasis Area and Severity Index (PASI) of 18.8, and concomitant psoriatic arthritis (PsA) received subcutaneous injections of 40 mg of adalimumab every other week (EOW). This was actually the dosage regimen recommended for PsA, as the drug had not then been approved for psoriasis at the time of the patients' enrolment. At week 12, an improvement of at least 50% of the PASI (PASI-50) was observed in 111 (77%) patients. Continuation of treatment in responders with adalimumab 40 mg EOW led to a sustained response, with the PASI-50 achieved by 97% of patients in the as-treated analysis at week 24 (PASI-75 in 82% and PASI-90 in 45% out of 109 patients who received EOW injections up to week 24). Thirty subjects who failed to attain the PASI-50 response at week 12 were treated with adalimumab 40 mg every week for a further 12 weeks. At week 24, 80% of these patients obtained a PASI-50 response after dose escalation. Tolerability was good in the majority of patients. Only two patients discontinued treatment because of an adverse event (repeated flu-like episodes and a pleuropericarditis of unknown origin, respectively).

AB - There is much evidence to show the efficacy of adalimumab, a human monoclonal antibody targeting tumour necrosis factor-alpha, in the treatment of plaque psoriasis. In this open-label experience, 147 high-need patients suffering from plaque psoriasis, with a mean Psoriasis Area and Severity Index (PASI) of 18.8, and concomitant psoriatic arthritis (PsA) received subcutaneous injections of 40 mg of adalimumab every other week (EOW). This was actually the dosage regimen recommended for PsA, as the drug had not then been approved for psoriasis at the time of the patients' enrolment. At week 12, an improvement of at least 50% of the PASI (PASI-50) was observed in 111 (77%) patients. Continuation of treatment in responders with adalimumab 40 mg EOW led to a sustained response, with the PASI-50 achieved by 97% of patients in the as-treated analysis at week 24 (PASI-75 in 82% and PASI-90 in 45% out of 109 patients who received EOW injections up to week 24). Thirty subjects who failed to attain the PASI-50 response at week 12 were treated with adalimumab 40 mg every week for a further 12 weeks. At week 24, 80% of these patients obtained a PASI-50 response after dose escalation. Tolerability was good in the majority of patients. Only two patients discontinued treatment because of an adverse event (repeated flu-like episodes and a pleuropericarditis of unknown origin, respectively).

KW - Adalimumab

KW - Dose escalation

KW - Psoriasis

KW - Response

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=62649149403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62649149403&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 227

EP - 233

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

IS - 1

ER -